van Houdt, Inge S <br/><br/>
Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression.  [electronic resource] 

 -  International journal of cancer  Aug 2008 
 - 609-15 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1097-0215 
<br/><br/><label>Standard No.: </label>10.1002/ijc.23543  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antigen-Presenting Cells--immunology<br/>Biomarkers, Tumor--analysis<br/>Biopsy<br/>CD4 Antigens--analysis<br/>CD56 Antigen--analysis<br/>CD8 Antigens--analysis<br/>Female<br/>Granzymes--analysis<br/>Histocompatibility Antigens Class I--analysis<br/>Histocompatibility Antigens Class II--analysis<br/>Humans<br/>Immunohistochemistry<br/>Kaplan-Meier Estimate<br/>Lymphatic Metastasis<br/>Lymphocyte Activation<br/>Lymphocytes, Tumor-Infiltrating<br/>Male<br/>Melanoma--immunology<br/>Middle Aged<br/>Neoplasm Staging<br/>Skin Neoplasms--immunology<br/>Treatment Outcome